Eradivir (Series A)

Funding Details
Awarder
Inbox
Date Award
September 25, 2024
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$10,250,000

Company Info
Founders
Martin Low
Company Description
Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.
Market
Immunotherapy
Location
West Lafayette, IN, USA

Links